RWE Submission for European Regulators and Payers: Challenges, Uncertainties, and Opportunities
Therapeutic Innovation & Regulatory Science · 2026-07 · 60 (4) · 929-933
DOI: 10.1007/s43441-026-00958-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Innovation & Regulatory Science, online erschienen am 26.03.2026. Verfasst von Lockwood Taylor und 1 weiteren Autor:innen. Beteiligte Einrichtung: Flatiron Health, 233 Spring Street, New York, NY, 10013, USA. lockwood.taylor@flatiron.com. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical, Drug Industry. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The new European Union Joint Clinical Assessment (JCA) process, effective January 2025, requires pharmaceutical companies to submit evidence within 100 days of notification. Key challenges include uncertainty about PICO (Population, Intervention, Comparator, Outcomes) parameters prior to PICO notification, limited timeframe for evidence generation, and need to reconcile differences between regulatory versus health technology assessment (HTA) evidence standards. Uncertainties involve predicting PICOs accurately and determining real-world evidence’s (RWE) appropriate role. However, opportunities exist for integrated evidence planning across clinical development, regulatory, and health economics and outcomes research (HEOR) teams, leveraging real-world data to inform or address PICOs as well as support regulatory evidence requirements. Early alignment between key functional teams, combined with proactive RWE use, is essential for generating fit-for-purpose evidence that satisfies the dual scrutiny of regulatory approval and HTA relative effectiveness assessment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Flatiron Health, 233 Spring Street, New York, NY, 10013, USA. lockwood.taylor@flatiron.com.
- Flatiron Health, 233 Spring Street, New York, NY, 10013, USA.
Zitieren
APA
Taylor, L., & Adamson, B. (2026). RWE Submission for European Regulators and Payers: Challenges, Uncertainties, and Opportunities. Therapeutic Innovation & Regulatory Science, 60(4), 929-933. https://doi.org/10.1007/s43441-026-00958-4
Vancouver
Taylor L, Adamson B. RWE Submission for European Regulators and Payers: Challenges, Uncertainties, and Opportunities. Therapeutic Innovation & Regulatory Science. 2026;60(4):929-933. doi:10.1007/s43441-026-00958-4
BibTeX
@article{Taylor2026,
author = {Taylor, Lockwood and Adamson, Blythe},
title = {RWE Submission for European Regulators and Payers: Challenges, Uncertainties, and Opportunities},
journal = {Therapeutic Innovation & Regulatory Science},
year = {2026},
volume = {60},
number = {4},
pages = {929--933},
doi = {10.1007/s43441-026-00958-4}
}
EUVIMED